Search Results
Your search for The ASCO ,The ASCO matches 21383 pages
Showing 12651 - 12700ASH Honors Marshall A. Lichtman, MD, With Lifetime Achievement in Hematology Award
The American Society of Hematology (ASH) will recognize Marshall A. Lichtman, MD, of the University of Rochester School of Medicine and Dentistry, with the 2017 Wallace H. Coulter Award for Lifetime Achievement in Hematology. Dr. Lichtman will be honored for his notable service to the field of...
The Dark Side of Medicine: Physician Suicide
The statistics on physician suicide are stark: Physicians are more than twice as likely to take their own lives as nonphysicians, and more than 400 physicians commit suicide each year in the United States. Moreover, young physicians at the early part of their training are reported to be...
NCI-COG Pediatric MATCH Trial to Test Targeted Drugs in Childhood Cancers
Investigators at the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) have announced the opening of enrollment for a unique precision medicine clinical trial. NCI-COG Pediatric Molecular Analysis for Therapy Choice (Pediatric MATCH) is a nationwide trial to explore whether...
WISDOM Study to Test Personalized Approach to Breast Cancer Screening
MANY health-care experts disagree about when screening mammography is appropriate and for whom. That’s what Women Informed to Screen Depending on Measures of Risk (WISDOM) seeks to remedy. The University of California (UC) Health study aims to uncover whether annual mammograms really are the best...
ACS Awards Grants to Reduce Colorectal Cancer Disparities in American Indian and Alaska Native Populations
The American Cancer Society (ACS) has awarded $100,000 in grants to five community health centers across the country to reduce colon cancer disparities in American Indian and Alaska Native populations through the Community Health Advocates implementing Nationwide Grants for Empowerment and Equity...
Bringing Oncology Care to Rural Communities
The organizations and programs listed here are helping to address and reduce disparities in cancer care in rural communities. ASCO University Disparities in Cancer Care: Take Action (http://university.asco.org/disparities-cancer-care-take-action). This free slide-based course is designed to help...
Stemming the Growing Cancer Crisis in Rural Appalachia
A pair of recent studies show a troubling trend: Despite a 20% decrease in cancer mortality rates nationwide over the past 2 decades,1 Americans living in rural regions of the United States are more likely to die of cancer than persons living in metropolitan areas of the country. An analysis of...
Rhodiola
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, Jun J. Mao, MD, MSCE, and Jyothirmai Gubili, MS, present information on...
Emotional and Psychological Distress Associated With Prostate Cancer
A cancer diagnosis presents emotional and psychological challenges for patients and caregivers, and prostate cancer has some unique challenges, in part because management is not writ in stone. At several points along the trajectory of illness, men with prostate cancer face decisions that can be...
Preexisting Dementia and Survival in Older Patients With Stage III Colon Cancer
A pre-existing diagnosis of dementia was associated with increased risk of death for older patients with advanced colon cancer; however, some of the effects of dementia on survival could be mediated by receipt of chemotherapy, according to results of a study published by Chen et al in Cancer...
Olaparib Receives Positive pCODR Recommendation for Treatment of BRCA-Mutated Ovarian Cancer
The pan-Canadian Oncology Drug Review (pCODR) has provided a positive clinical recommendation for the reimbursement of olaparib (Lynparza), a first-of-its-kind treatment for BRCA-mutated ovarian cancer. Lynparza is an oral, potent inhibitor of poly (ADP-ribose) polymerase (PARP) available as a...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Benin
The ASCO Post is pleased to continue this special feature on the worldwide cancer burden. Each installment focuses on a country from one of the six regions of the world, as defined by the World Health Organization (ie, Africa, the Americas, South-East Asia, Europe, Eastern Mediterranean, and...
Overdiagnosis of Those in Higher Income Brackets
According to researchers from the Dartmouth Institute for Health Policy and Clinical Practice, being in a high-income bracket may lead to overdiagnosis of cancer and the subsequent harms associated with unnecessary medical treatments. To shed light on this interesting finding and its broader...
Fox Chase Cancer Center Announces New Faculty, Appointments
Under the direction of Martin J. Edelman, MD, Chair, Department of Hematology/Oncology, who joined Fox Chase Cancer Center earlier this year, the department has been reorganized into four sections: Hematologic Malignancies, Solid Tumor Oncology, General Hematology/Oncology, and Fox Chase at Temple...
Douglas R. Lowy, MD, and John T. Schiller, PhD, Receive 2017 Lasker Award
Two scientists at the National Cancer Institute (NCI) received the 2017 Lasker-DeBakey Clinical Medical Research Award for their significant research leading to the development of human papillomavirus (HPV) vaccines. The award is the country’s most prestigious biomedical research prize and was...
Survivorship Resources for Providers and Patients
ASCO OFFERS a bundled resource that combines provider and patient information about cancer survivorship. Providing High Quality Survivorship Care in Practice: An ASCO Guide aims to assist oncologists and other clinicians with implementing high-quality survivorship care programs within their...
ANCO Supports Young Investigator Award for a Northern California Researcher
The Association of Northern California Oncologists (ANCO), an ASCO Affiliate, is among the newest nonprofit supporters of the Conquer Cancer Foundation of the American Society of Clinical Oncology (CCF). ANCO is generously funding a 2018 Young Investigator Award (YIA) for a qualified northern...
Are You Ready for October 2? Plan Ahead for Key QPP Deadline
AS PRACTICES across the country implement the Quality Payment Program (QPP), it’s important to remember that 2017 is a transition year. Practices only have to report one measure for one patient (including at least one Medicare patient) in order to receive a neutral payment adjustment and avoid...
Talking About Physician Burnout: Practical Strategies for Starting the Conversation
Would you rather explain the benefits of three cycles of bleomycin, etoposide, and cisplatin to a hostile crowd of bored teenagers than talk to your program director, supervisor, or colleagues about feeling burned out? It is an understandable feeling. Professional burnout is a difficult concept to...
Original Report in JCO CCI Describes How Authors Developed a Process to Automate a QOPI Measure
A NEW ARTICLE published in JCO Clinical Cancer Informatics (JCO CCI), “Automating QOPI Quality Measure NHL78a,” by Richard P. Mansour, MD, and Samip Master, MD, reports how the authors were able to use data from an electronic health record (EHR) and Microsoft SQL Server database management system...
#WECONQUERCANCER
JOIN THE Conquer Cancer Foundation community of supporters to start a personal fundraising campaign and help create a world free from the fear of cancer. What will you do to help conquer cancer? Honor/remember a loved one Celebrate a special occasion Participate in an endurance event Start...
Clinical Practice Committee, State Affiliate Council Support Innovative Clinical Research—And So Can You
ASCO’s Clinical Practice Committee (CPC) and State Affiliate Council (SAC) have a history of supporting the Conquer Cancer Foundation of ASCO (CCF) Young Investigator Award (YIA) program. Individual members of the CPC and SAC, as well as ASCO State Affiliates, contribute funds to this philanthropic ...
AMA Applauds Surgeon General Nominee
DAVID O. BARBE, MD, President of the American Medical Association (AMA), issued the following statement: "The American Medical Association strongly supports the nomination of Jerome Adams, MD, to become the next Surgeon General of the United States. As Indiana State Health Commissioner, Dr. Adams ...
Gary Kohanbash, PhD, Receives Grant From St. Baldrick’s Foundation
GARY KOHANBASH, PhD, a neuro-oncology researcher at the Children’s Hospital of Pittsburgh of the University of Pittsburgh Medical Center, has been awarded a scholar grant of $298,000 from the St. Baldrick’s Foundation, a volunteer-driven charity dedicated to raising money for childhood cancer...
Kunle Odunsi, MD, PhD, FRCOG, FACOG, Named to NIH Immunology Grant Review Board
KUNLE ODUNSI, MD, PHD, FRCOG, FACOG, Deputy Director of Roswell Park Cancer Institute, has been appointed to the Transplantation, Tolerance, and Tumor (TTT) Immunology Study Section within the National Institutes of Health (NIH) Center for Scientific Review. The TTT section is the panel of peer...
NCCN Guidelines to Be Integrated Into Evinance Decision Support Platform
THE NATIONAL COMPREHENSIVE Cancer Network® (NCCN®) is collaborating with Evinance to integrate the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) into the Evinance Decision Support Platform to allow for point-of-care access to treatment recommendations derived from the NCCN...
U.S. Preventive Services Task Force Recommends Screening Most Adult Women for Cervical Cancer
THE U.S. PREVENTIVE SERVICES TASK FORCE has posted a draft recommendation statement and draft evidence review on screening for cervical cancer. The Task Force recommends that primary care clinicians screen for cervical cancer in women ages 21 to 29 every 3 years with cervical cytology, more...
Balancing Harms and Benefits of Cancer Screening: The Debate Continues
Over the past several decades, widespread cancer screening has saved lives from various cancer types. However, despite advances in early-detection technologies, many cancers still remain undetected until they become symptomatic, conferring poor prognoses and outcomes. Moreover, some methods of...
How Early Palliative Care May Benefit Patients With Incurable Cancer
Palliative care provided soon after a patient is diagnosed with incurable cancer not only helps improve the patient’s overall quality of life but also improves communication about the patient’s wishes for end-of-life care, according to a study by Jennifer S. Temel, MD, Clinical Director of Thoracic ...
FDA Recent Approvals Include First Oncology Biosimilar
ON SEPTEMBER 14, 2017, the U.S. Food and Drug Administration (FDA) approved bevacizumab-awwb (Mvasi) as a biosimilar to bevacizumab (Avastin) for the treatment of multiple types of cancer. Bevacizumab-awwb is the first biosimilar approved in the United States for the treatment of cancer....
Duration Studies in Oncology Have Often Been Poorly Designed and Analyzed
The ASCO Post is pleased to introduce “At Microphone 1,” an occasional column written by Steven E. Vogl, MD, of Bronx, New York. When he’s not in his clinic, Dr. Vogl can generally be found at major oncology meetings, and often at the microphone where he stands ready with important questions for...
News From JCO and JOP
STAYING UP-TO-DATE in the fast-paced world of oncology literature is a daunting task at best. To assist with that task, The ASCO Post has assembled an assortment of studies recently published in the Journal of Clinical Oncology (JCO) and the Journal of Oncology Practice (JOP). Future installments...
Sarcoma Management Is Slowly Evolving
THE BACKBONE treatment for soft-tissue sarcomas has long been anthracycline-based, but new approaches are coming. These novel strategies were discussed at the 2017 Debates and Didactics in Hematology and Oncology Conference in Sea Island, Georgia, by Melinda L. Yushak, MD, MPH, Assistant Professor ...
Small Steps Forward in Brain Tumor Therapy
SOME RECENT ADVANCES in the treatment of brain tumors are promising, but others are less so, according to Jeffrey J. Olson, MD, Professor of Neurosurgery at Emory University, Atlanta. At the 2017 Debates and Didactics in Hematology and Oncology Conference, held in Sea Island, Georgia, and...
Weill Cornell Medicine Awarded $11.3 Million Grant for Prostate Cancer Research
Weill Cornell Medicine has been awarded a 5-year, $11.3 million Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI) to improve the detection, diagnosis, and treatment of prostate cancer. Established in 1992, SPORE grants serve as the cornerstone of...
Tibetan Yoga Practice May Improve Sleep Quality for Patients With Breast Cancer Undergoing Chemotherapy
Participating in twice-weekly practice of Tibetan yoga may reduce sleep disturbances and improve sleep quality in breast cancer patients receiving chemotherapy, according to a study published by Chaoul et al in Cancer. The study, led by researchers from The University of Texas MD Anderson Cancer...
Positive Results from Phase III MURANO Trial Evaluating Venetoclax in Combination With Rituximab in Relapsed/Refractory CLL
The phase III MURANO study of venetoclax (Venclexta) tablets in combination with rituximab (Rituxan) met its primary endpoint. Results showed that the combination prolonged progression-free survival in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) compared with bendamustine...
AACR Releases 2017 Cancer Progress Report: Harnessing Research Discoveries to Save Lives
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives...
Assessing and Managing CAR T-Cell Treatment Toxicities
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists—one addressed by a team led by clinicians at The University of Texas MD Anderson Cancer Center with proposed guidelines for...
New ASCO Guideline Aims to Improve Clinician Communication With Patients
A new guideline from ASCO published by Gilligan et al in the Journal of Clinical Oncology outlines best practices for cancer clinicians when communicating with patients and their loved ones. The Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline...
Peter W.T. Pisters, MD, MHCM, Named Sole Finalist in Search for President, MD Anderson
The University of Texas System Board of Regents has selected Peter W.T. Pisters, MD, MHCM, as sole finalist for the position of president at The University of Texas MD Anderson Cancer Center in Houston. The regents voted unanimously to select Dr. Pisters at a special board meeting on Friday,...
ESMO 2017: KEYNOTE-045: Updated Results Support Pembrolizumab as Second-Line Treatment in Advanced Urothelial Cancer
Mature results from the KEYNOTE-045 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract LBA37_PR) confirmed significantly longer survival in patients with advanced urothelial cancer who received the checkpoint inhibitor pembrolizumab after initial...
ESMO 2017: 'Triggers': A New Tool to Assess Patients’ Palliative Needs
A new tool to identify patients who would benefit from early palliative care was presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract LBA54_PR). The so-called “Triggers” tool, developed by the London Cancer Alliance to help clinicians in the...
NCCN Guidelines to Include Categories of Preference
The National Comprehensive Cancer Network® (NCCN®) has instituted Categories of Preference for recommendations within the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Initially, Categories of Preference will be published for drugs and biologics recommended within...
ESMO 2017: Patients Struggle With Key Aspects of Clinical Trial Methodology
Clinical trials are fundamental to the development of new treatments for cancer, yet the annual accrual to cancer clinical trials worldwide is low, estimated at 3%–5%. A nationwide study in Ireland, the preliminary results of which were presented at the European Society for Medical Oncology...
ESMO 2017: KEYNOTE-040 Evaluates Pembrolizumab in Head and Neck Cancer
Immunotherapy with the checkpoint inhibitor pembrolizumab (Keytruda) may be a better option than standard treatments for patients whose head and neck cancer has spread or recurred after an initial round of chemotherapy, according to results of the KEYNOTE-040 trial presented at the European Society ...
ESMO 2017: Abdominal to Peripheral Fat Ratio May Predict Risk of Cancer Diagnosis in Postmenopausal Women
Body fat distribution in the trunk is more influential than body weight when it comes to cancer risk in postmenopausal women, according to a study presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract 1408P_PR). The findings put a new spin on weight...
ESMO 2017: MONARCH 3: Abemaciclib as Initial Therapy Improves Outcome in Endocrine-Sensitive Advanced Breast Cancer
The results of the MONARCH 3 trial, presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract 236O_PR), showed that adding the cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib to endocrine therapy improved progression-free survival compared to endocrine...
ESMO 2017: NOR-CAYACS Trial: Factors That May Limit Work Ability of Young Adult Cancer Survivors
Factors that may limit the ability of young adult cancer survivors to work were reported at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract 1110PD_PR). Late side effects can occur months or years after cancer treatment. In patients diagnosed with cancer in young...
FDA Approves Copanlisib for Adults With Relapsed Follicular Lymphoma
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to copanlisib (Aliqopa) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies. “For patients with relapsed follicular lymphoma, the cancer often...
